Biohaven Licenses IgG Degrader Portfolio to Ono for $80 Million Upfront
Biohaven signed a collaboration and license agreement with Ono Pharmaceutical covering development and commercialization of its MoDE pan-IgG degrader portfolio in Japan, South Korea, Taiwan and ASEAN countries. The deal includes an $80 million upfront payment at closing and 20% royalties.